search
Back to results

Influence of Inflammation on Micronutrient Status Assessment

Primary Purpose

Healthy Infants

Status
Completed
Phase
Not Applicable
Locations
Bangladesh
Study Type
Interventional
Intervention
Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
Sponsored by
International Centre for Diarrhoeal Disease Research, Bangladesh
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Healthy Infants focused on measuring vitamin A, vitamin A isotope, vitamin D, ferritin, transferrin receptor, folate, cobalamin, beta-carotene, Inflammation

Eligibility Criteria

9 Months - 18 Months (Child)All SexesAccepts Healthy Volunteers

Inclusion criteria:

  1. 9 - 18 months of age
  2. Infants with normal body temperature and normal CRP (<5 mg/L)
  3. Infants receive breast milk from the mother at least once per day
  4. Mothers produce a breast milk containing 30-40 nmol vitamin A /g milk fat
  5. Infants received a high-dose vitamin A capsules at the time of the most recent national distribution campaign (within the last 2-4 months)
  6. Mother is 18 - 45 years of age
  7. Mother and her infant plan to stay in the study area for the duration of the study

Exclusion criteria:

  1. Mother or infant has chronic disease
  2. Mother or infant has acute illness on the day of data collection
  3. Infant is anemic (Hb <90 g/L)
  4. Infant has weight for length <80% of the reference median
  5. Infants do not develop inflammation (CRP ≥5 mg/L) after PENTA vaccination

Sites / Locations

  • Clinical Trail Unit (CTU), icddr,b.
  • Shaikh M Ahmad

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Healthy infants

Infants with an inflammatory condition

Arm Description

Investigators will also use pentavalent (PENTA) vaccine as a means to induce controlled inflammation (closely mimic to natural infection). PENTA is a combination of five different vaccine antigens (Hepatitis B (HBV)/ Haemophilus influenza type b (Hib) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).

Outcomes

Primary Outcome Measures

Inflammation marker C-reactive protein (CRP) levels in infants before and 1-day after inflammation
In infants (9-18 mo) plasma CRP levels (mg/L) will be estimated by ELISA before and 24 hours after inflammation. Paired t-test will be used to evaluate the difference.
Vitamin A status in infants before and 1-day after inflammation
In infants (9-18 mo) plasma retinol levels (nmol/L) will be estimated by HPLC before and 24 hours after inflammation.Paired t-test will be used to evaluate the difference.
Total body stores (TBS) of vitamin A in infants before and 1-day after inflammation
In infants (9-18 mo) TBS of vitamin A (nmol) will be estimated before and 24 hours after inflammation. TBS will be measured by calculating the specific activities of 13C10- and 13C4- retinyl acetate in the blood samples by using liquid chromatography-tandem mass spectrometry (LC/MS/MS) method. Paired t-test will be used to evaluate the difference.
Iron status in infants before and 1-day after inflammation
In infants (9-18 mo) plasma ferritin levels (ug/L) will be estimated by ELISA before and 24 hours after inflammation. Paired t-test will be used to evaluate the difference.
Iron status in infants before and 1-day after inflammation
In infants (9-18 mo) plasma soluble transferrin receptor (sTfR) concentration (mg/L) will be estimated by ELISA before and 24 hours after inflammation. Paired t-test will be used to evaluate the difference.

Secondary Outcome Measures

Full Information

First Posted
March 29, 2018
Last Updated
August 21, 2019
Sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh
Collaborators
Newcastle University, UK
search

1. Study Identification

Unique Protocol Identification Number
NCT03801161
Brief Title
Influence of Inflammation on Micronutrient Status Assessment
Official Title
Influence of Inflammation on Micronutrient Status Assessment
Study Type
Interventional

2. Study Status

Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
June 1, 2018 (Actual)
Primary Completion Date
March 31, 2019 (Actual)
Study Completion Date
June 30, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh
Collaborators
Newcastle University, UK

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Inflammation can influence several biochemical measurements those commonly used to interpret micronutrient status in children. Our primary objective is to investigate the effects of inflammation on several biochemical measurements used to interpret micronutrient status in children. A total of 40 infants (9-18 mo of age) will participate in this study. Investigators will use PENTA vaccines as a means to induce controlled inflammation (closely mimic to natural infection). PENTA is a combination of five different vaccine antigens (Hepatitis B (HBV)/ Haemophilus influenza type b (Hib) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)). The investigators will also use two different stable isotopic retinols for the assessment of total body vitamin A stores. Baseline blood samples (5 mL) will be obtained from all infants and then randomly selected 30 infants will receive PENTA vaccines, while the other 10 infants will receive no vaccines. 24 hours after vaccination a finger-prick blood sample will be obtained from the infants in the vaccinated group to measure CRP and on the same day, blood samples (5 mL) will be obtained from infants who develop inflammation (CRP> 5mg/L) in the vaccine group and also from infants in the control group. Thus estimated plasma micronutrients and vitamin A stores before and after inflammation will calculate the effects of inflammation on the interpretation of micronutrient deficiencies based on biochemical indicator assessment.
Detailed Description
Background: Subclinical micronutrient deficiencies remain a hidden aspect of malnutrition for which comprehensive data are lacking. Defining subclinical micronutrient deficiencies requires considering the prevalence of inflammation and its implications for the interpretation of micronutrient deficiencies based on biochemical indicator assessment. This study will provide a comprehensive profile of micronutrient status and antimicrobial resistance in a cohort of young children living in the densely populated urban slum. Hypothesis: I. Inflammation can influence several biochemical measurements those commonly used to interpret micronutrient status in children II. Micronutrient assessments can be performed successfully using finger/heel prick blood samples with microsamplers, thus increasing the ease of blood collection and reducing costs for cold storage and transport to the analytical laboratory. Specific Objectives: Our primary objective is to investigate the effects of inflammation on several biochemical measurements used to interpret micronutrient status in children. Our secondary aim is to test the applicability of a blood spot device allowing the determination of micronutrient status in field settings. Our exploratory objective is to make a comparative analysis of gut antimicrobial resistance genes (AMR) and resistome profile in children. Methods: A total of 40 infants (9-18 mo of age) will participate in this study. In this study, investigators will use two different stable isotopic vitamin A e.g., 13C10-retinyl acetate and 13C4-retinyl acetate. 400 μg of these isotopes, dissolved in 0.5 mL of sunflower oil, will be provided directly into the infant's mouth by using a direct replacement pipette. Mothers will be asked to breastfeed their infant after oral dosing to enhance absorption of the labeled vitamin A. Specific activity of 13C10- and 13C4- retinyl acetate in the blood samples will be measured by liquid chromatography-tandem mass spectrometry (LC/MS/MS). On the day of blood collection, a 24-h dietary recall and weekly morbidity questionnaires will be used. Investigators will also use PENTA vaccines as a means to induce controlled inflammation (closely mimic to natural infection). PENTA is a combination of five different vaccine antigens (Hepatitis B (HBV)/ Haemophilus influenza type b (Hib) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)). This vaccination is beneficial to the infants since the World Health Organization recommends a booster vaccination dose. At the end of the study, PENTA vaccines will also be provided to the study infants in the "no-vaccine" group. On day 0, all infants (n=40) will receive an oral dose of 13C10-retinyl acetate, and blood samples (5 mL) will be taken on day 4. On day 7 all infants (n=40) will also receive another oral dose of 13C4-retinyl acetate. 3-day later randomly selected 30 infants will receive PENTA vaccines (day 10), while the other 10 infants will receive no vaccines. 24 hours after vaccination a finger-prick blood sample will be obtained from the infants in the vaccinated group to measure CRP (QuikRead go, Orion, Finland). On the same day (day 11), blood samples (5 mL) will be obtained from infants who develop inflammation (CRP> 5mg/L) in the vaccine group and also from infants in the control group (day 11). Thus plasma micronutrients and vitamin A stores estimates on day 4 and day 11 will evaluate the effects of inflammation on the plasma micronutrient status indicators and total body vitamin A store. Blood microsamplers will be tested alongside venous blood collection to assess the feasibility of finger/heel prick sampling. Fecal samples, local surface water, and wastewater samples will be collected to test the prevalence of AMR resitomes in children and their environment. Outcome measures/variables: The following plasma biomarkers will be estimated before inflammation and 24 hours after inflammation Inflammation markers: C-reactive protein (CRP) (mg/L) and α1-acid glycoprotein (AGP) (g/L) Vitamin A status indicators: retinol (nmol/L), total body vitamin A stores (nmol), Retinol binding protein (RBP) (mg/L) and beta-carotene (nmol/L) Iron status indicators: ferritin (ug/L) and soluble transferrin receptor (mg/L) Folate/B12 status indicators: folate (nmol/L), methylmalonic acid (umol/L) and cobalamin (pmol/L) Trace element status indicators: selenium (ug/L), copper (ug/L) and thyroglobulin (ug/L). The usefulness of a microsampler device to collect blood samples for future micronutrient assessments. Assessment and contrast of AMR gene abundances and diversity to develop resistomes

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy Infants
Keywords
vitamin A, vitamin A isotope, vitamin D, ferritin, transferrin receptor, folate, cobalamin, beta-carotene, Inflammation

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
75 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Healthy infants
Arm Type
No Intervention
Arm Title
Infants with an inflammatory condition
Arm Type
Experimental
Arm Description
Investigators will also use pentavalent (PENTA) vaccine as a means to induce controlled inflammation (closely mimic to natural infection). PENTA is a combination of five different vaccine antigens (Hepatitis B (HBV)/ Haemophilus influenza type b (Hib) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
Intervention Type
Biological
Intervention Name(s)
Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
Intervention Description
Pentavalent vaccine is being recommended to provide infants at 6wk, 10wk and 14wk of age. This vaccine also induces plasma CRP >5 mg/L in infants within 24 hours of immunization.
Primary Outcome Measure Information:
Title
Inflammation marker C-reactive protein (CRP) levels in infants before and 1-day after inflammation
Description
In infants (9-18 mo) plasma CRP levels (mg/L) will be estimated by ELISA before and 24 hours after inflammation. Paired t-test will be used to evaluate the difference.
Time Frame
24 hours
Title
Vitamin A status in infants before and 1-day after inflammation
Description
In infants (9-18 mo) plasma retinol levels (nmol/L) will be estimated by HPLC before and 24 hours after inflammation.Paired t-test will be used to evaluate the difference.
Time Frame
24 hours
Title
Total body stores (TBS) of vitamin A in infants before and 1-day after inflammation
Description
In infants (9-18 mo) TBS of vitamin A (nmol) will be estimated before and 24 hours after inflammation. TBS will be measured by calculating the specific activities of 13C10- and 13C4- retinyl acetate in the blood samples by using liquid chromatography-tandem mass spectrometry (LC/MS/MS) method. Paired t-test will be used to evaluate the difference.
Time Frame
24 hours
Title
Iron status in infants before and 1-day after inflammation
Description
In infants (9-18 mo) plasma ferritin levels (ug/L) will be estimated by ELISA before and 24 hours after inflammation. Paired t-test will be used to evaluate the difference.
Time Frame
24 hours
Title
Iron status in infants before and 1-day after inflammation
Description
In infants (9-18 mo) plasma soluble transferrin receptor (sTfR) concentration (mg/L) will be estimated by ELISA before and 24 hours after inflammation. Paired t-test will be used to evaluate the difference.
Time Frame
24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
9 Months
Maximum Age & Unit of Time
18 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria: 9 - 18 months of age Infants with normal body temperature and normal CRP (<5 mg/L) Infants receive breast milk from the mother at least once per day Mothers produce a breast milk containing 30-40 nmol vitamin A /g milk fat Infants received a high-dose vitamin A capsules at the time of the most recent national distribution campaign (within the last 2-4 months) Mother is 18 - 45 years of age Mother and her infant plan to stay in the study area for the duration of the study Exclusion criteria: Mother or infant has chronic disease Mother or infant has acute illness on the day of data collection Infant is anemic (Hb <90 g/L) Infant has weight for length <80% of the reference median Infants do not develop inflammation (CRP ≥5 mg/L) after PENTA vaccination
Facility Information:
Facility Name
Clinical Trail Unit (CTU), icddr,b.
City
Dhaka
ZIP/Postal Code
1212
Country
Bangladesh
Facility Name
Shaikh M Ahmad
City
Dhaka
ZIP/Postal Code
1212
Country
Bangladesh

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Influence of Inflammation on Micronutrient Status Assessment

We'll reach out to this number within 24 hrs